• 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯𝟬–𝟲𝟬 𝗞𝗚 (𝗔𝗳𝗼𝘅𝗼𝗹𝗮𝗻𝗲𝗿 + 𝗠𝗶𝗹𝗯𝗲𝗺𝘆𝗰𝗶𝗻 𝗢𝘅𝗶𝗺𝗲): 𝗔 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗔𝗻𝘁𝗶𝗽𝗮𝗿𝗮𝘀𝗶𝘁𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲
SPECTRA FOR DOGS 30–60 KG is a veterinary antiparasitic chewable formulation containing afoxolaner and milbemycin oxime. The 30–60 kg presentation is designed for dogs weighing more than 30 kg and up to 60 kg, according to the applicable product information. Afoxolaner belongs to the isoxazoline class and provides systemic activity against susceptible fleas and ticks. Milbemycin oxime belongs to the macrocyclic lactone class and is active against susceptible nematode parasites.
The combination provides complementary control of important external and internal parasites and contributes to heartworm prevention when used according to the approved veterinary regimen. The appropriate weight-band presentation should be selected using the dog's current body weight. Veterinary guidance is recommended for dogs with existing medical conditions, neurological disorders, pregnancy, lactation, or concurrent medication use.
• 𝗞𝗲𝘆 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯𝟬–𝟲𝟬 𝗞𝗚
1. Helps control susceptible flea infestations in dogs within the specified weight range.
2. Provides systemic activity against susceptible tick species.
3. Helps control susceptible gastrointestinal nematodes.
4. Supports heartworm prevention when administered according to the approved veterinary schedule.
5. Combines external and internal parasite control in a convenient oral chewable formulation.
• 𝗛𝗼𝘄 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯𝟬–𝟲𝟬 𝗞𝗚 𝗪𝗼𝗿𝗸𝘀
Afoxolaner acts on ligand-gated chloride channels in susceptible arthropods, including GABA-gated and glutamate-gated chloride channels, disrupting normal neuronal transmission and causing paralysis and death of susceptible fleas and ticks. Milbemycin oxime binds to glutamate-gated chloride channels in susceptible nematodes, increasing chloride-ion permeability and producing neuromuscular paralysis. Together, these mechanisms provide activity against susceptible external and internal parasites, while milbemycin oxime contributes to heartworm prevention by acting against developing heartworm larvae when administered according to the approved regimen.
• 𝗨𝘀𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯𝟬–𝟲𝟬 𝗞𝗚
1. Dosage: Use the 30–60 kg presentation for dogs weighing more than 30 kg and up to 60 kg. Follow the exact dosage and treatment schedule stated on the approved product label.
2. Administration: Administer orally as a chewable tablet. Do not substitute another weight-band presentation without veterinary advice.
3. Timing: For indications requiring ongoing prevention, administer at the interval specified by the approved veterinary regimen and maintain the schedule consistently.
4. Monitoring: Observe the dog after administration and seek veterinary assessment if persistent or significant adverse reactions occur.
5. Precautions: Accurately weigh the dog before treatment and consult a veterinarian before use in dogs with neurological disorders, significant medical conditions, or concurrent medication use.
• 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯𝟬–𝟲𝟬 𝗞𝗚
1. Afoxolaner provides systemic activity against susceptible fleas and ticks.
2. Milbemycin oxime provides activity against susceptible gastrointestinal nematodes.
3. The combination provides coverage against multiple parasite groups through one oral veterinary formulation.
4. Regular administration can help maintain parasite prevention when the product is used according to the approved schedule.
5. The 30–60 kg presentation supports weight-based dosing for dogs within the specified body-weight range.
𝗡𝗢𝗧𝗘: Veterinary medicines may be subject to prescription and dispensing restrictions depending on the country. Use SPECTRA FOR DOGS according to the locally approved product information and veterinary advice.
• 𝗢𝗳𝗳-𝗟𝗮𝗯𝗲𝗹 𝗨𝘀𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟯𝟬–𝟲𝟬 𝗞𝗚
Off-label use refers to administering a veterinary medicine in a manner that differs from its approved label, including use for an unapproved indication, parasite, dosing regimen, or animal population. Such use should only be considered by a veterinarian following an individual clinical assessment.
1. A veterinarian may consider an alternative treatment regimen for a susceptible parasitic condition when supported by available evidence and professional judgment.
2. A veterinarian may consider an active ingredient for a clinical circumstance that is not specifically listed on the local product label when medically appropriate.
3. An alternative treatment strategy may occasionally be considered when standard labelled options are unsuitable for an individual dog.
Disclaimer: Off-label uses should only occur under veterinarian supervision and may not be approved in all countries.
• 𝗘𝘅𝗽𝗲𝗿𝘁 𝗔𝗱𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 𝗢𝗽𝘁𝗶𝗺𝗮𝗹 𝗨𝘀𝗲
1. Confirm the dog's current body weight before selecting the 30–60 kg presentation.
2. Maintain the recommended dosing interval for ongoing parasite prevention.
3. Do not use a different weight-band tablet unless advised by a veterinarian.
4. Inform the veterinarian about all medicines, supplements, and other antiparasitic products the dog receives.
5. Dogs with a history of seizures or neurological disorders should be evaluated before receiving an isoxazoline-containing medicine.
6. Contact a veterinarian if significant vomiting, diarrhea, lethargy, tremors, ataxia, seizures, or other unexpected reactions occur after administration.
• 𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝘀
• 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗛𝗲𝗮𝗹𝘁𝗵
Dogs with significant cardiovascular disease should be assessed by a veterinarian before starting or changing an antiparasitic regimen. Dogs at risk of heartworm disease should receive appropriate preventive care, while suspected established heartworm infection requires veterinary diagnosis and management.
• 𝗟𝗶𝘃𝗲𝗿 & 𝗞𝗶𝗱𝗻𝗲𝘆 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻
Dogs with significant liver or kidney impairment should be evaluated by a veterinarian before treatment. The veterinarian can consider the animal's health status, concurrent medicines, and applicable product information when determining suitability.
• 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 & 𝗕𝗿𝗲𝗮𝘀𝘁𝗳𝗲𝗲𝗱𝗶𝗻𝗴
Use during pregnancy or lactation should follow the specific product's approved veterinary information. Breeding animals should not receive treatment outside labelled recommendations without veterinary guidance.
• 𝗗𝗿𝘂𝗴 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀
Tell the veterinarian about all prescription medicines, supplements, and other parasite-control products the dog is receiving. Avoid combining antiparasitic medicines without professional veterinary guidance.
• 𝗘𝘅𝗶𝘀𝘁𝗶𝗻𝗴 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀
Dogs with a history of seizures or neurological disorders should be evaluated before treatment. Isoxazoline-class medicines have been associated with neurological adverse reactions, including tremors, ataxia, and seizures, in some animals.
• 𝗦𝘁𝗼𝗿𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀
1. Store according to the manufacturer's labelled storage conditions.
2. Keep the chewable tablets in their original packaging until administration.
3. Protect the product from excessive heat, moisture, and direct sunlight.
4. Keep out of reach of children and animals for which the medicine was not intended.
5. Do not use the product after its expiry date or if the packaging is damaged.
• 𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆 𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 (𝗙𝗔𝗤𝘀)
• Q: What is SPECTRA FOR DOGS 30–60 KG?
A: SPECTRA FOR DOGS 30–60 KG is a veterinary antiparasitic chewable formulation containing afoxolaner and milbemycin oxime for dogs weighing more than 30 kg and up to 60 kg, according to the applicable product label.
• Q: What are the active ingredients in SPECTRA FOR DOGS?
A: The active ingredients are afoxolaner and milbemycin oxime. The exact strength should be confirmed from the manufacturer's packaging and locally approved product information.
• Q: What parasites does SPECTRA FOR DOGS help control?
A: Depending on the approved indication, the combination provides activity against susceptible fleas, ticks, gastrointestinal nematodes, and contributes to heartworm prevention.
• Q: How often is SPECTRA FOR DOGS administered?
A: For indications requiring ongoing prevention, it is generally administered once monthly according to the approved veterinary dosing schedule.
• Q: Can SPECTRA FOR DOGS be given to dogs weighing more than 60 kg?
A: The 30–60 kg presentation is intended for dogs within its labelled weight range. Dogs outside this range should receive the appropriate weight-based presentation or combination only as directed by a veterinarian.
• Q: Can SPECTRA FOR DOGS be used in dogs with seizures?
A: Dogs with a history of seizures or neurological disorders should be evaluated by a veterinarian before treatment because neurological adverse reactions have been reported with isoxazoline-class medicines.
• Q: Is SPECTRA FOR DOGS a prescription medicine?
A: Regulatory status varies between countries and jurisdictions. Follow the applicable local veterinary prescription, dispensing, and administration requirements.
